Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002165 · ClinicalTrials.gov registry record · NA
Viracept Expanded Access Program
A NA study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00002165 is a NA study that has completed, run by Agouron Pharmaceuticals.
The verdict
NCT00002165, a NA study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of \<= 50. To obtain additional information on the safety profile of nelfinavir mesylate (Viracept). (PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
Interventions
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002165
The ClinicalTrials.gov registry entry for NCT00002165 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002165 about?
NCT00002165 is a clinical study titled "Viracept Expanded Access Program". To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of \<= 50. To obtain additional information on the ...
What is the current status of trial NCT00002165?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002165?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002165?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.